Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Lung Cancer

  Free Subscription

Articles published in J Nucl Med

Retrieve available abstracts of 21 articles:
HTML format

Single Articles

    November 2023
  1. QUAN Z, Han Z, Yang Y, Wang J, et al
    Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
    J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002.
    PubMed     Abstract available

    July 2023
  2. KERSTING D, Sandach P, Sraieb M, Wiesweg M, et al
    (68)Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.
    J Nucl Med. 2023 Jul 20:jnumed.123.265664. doi: 10.2967/jnumed.123.265664.
    PubMed     Abstract available

    June 2023
  3. WATABE T, Naka S, Tatsumi M, Kamiya T, et al
    Initial Evaluation of [(18)F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions.
    J Nucl Med. 2023 Jun 2:jnumed.123.265486. doi: 10.2967/jnumed.123.265486.
    PubMed     Abstract available

    April 2023
  4. COLOVIC M, Yang H, Southcott L, Merkens H, et al
    Comparative Evaluation of [(18)F]5-Fluoroaminosuberic Acid and (4S)-4-3-[(18)F]fluoropropyl)-l-Glutamate as System xC--Targeting Radiopharmaceuticals.
    J Nucl Med. 2023 Apr 28:jnumed.122.265254. doi: 10.2967/jnumed.122.265254.
    PubMed     Abstract available

    December 2022
  5. SHIYAM SUNDAR LK, Hacker M, Beyer T
    Whole-body PET imaging: A catalyst for whole-person research?
    J Nucl Med. 2022 Dec 2:jnumed.122.264555. doi: 10.2967/jnumed.122.264555.
    PubMed     Abstract available

    August 2022
  6. BOULEAU A, Nozach H, Dubois S, Kereselidze D, et al
    Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of (89)Zr-Labeled Anti-PD-L1 Antibody Formats.
    J Nucl Med. 2022;63:1259-1265.
    PubMed     Abstract available

    June 2022
  7. STERBIS E, Liang R, Trivedi P, Kwak J, et al
    Lack of adherence to guideline-based imaging prior to subsequent radiation in patients with non-small cell lung cancer: Impact on patient outcomes.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264131. doi: 10.2967/jnumed.122.264131.
    PubMed     Abstract available

    April 2022
  8. KUNIHIRO AG, Sarrett SM, Lastwika KJ, Solan JL, et al
    CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer.
    J Nucl Med. 2022 Apr 28. pii: jnumed.121.263511. doi: 10.2967/jnumed.121.263511.
    PubMed     Abstract available

    March 2022
  9. BUCK AK, Haug A, Dreher N, Lambertini A, et al
    Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using (68)Ga-PentixaFor PET.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263693. doi: 10.2967/jnumed.121.263693.
    PubMed     Abstract available

  10. YUSUFALY TI, Mell LK
    Reply: Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful.
    J Nucl Med. 2022;63:495.

  11. ZHANG L, Zhang B
    Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful.
    J Nucl Med. 2022;63:494-495.

    February 2022
  12. ZIDAN L, Iravani A, Oleinikov K, Ben-Haim S, et al
    Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
    J Nucl Med. 2022;63:218-225.
    PubMed     Abstract available

    December 2021
  13. KOLINGER GD, Vallez Garcia D, Kramer GM, Frings V, et al
    Effects of tracer uptake time in non-small cell lung cancer (18)F-FDG PET radiomics.
    J Nucl Med. 2021 Dec 21. pii: jnumed.121.262660. doi: 10.2967/jnumed.121.262660.
    PubMed     Abstract available

    August 2021
  14. FARWELL MD, Gamache RF, Babazada H, Hellmann MD, et al
    CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of (89)Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262485. doi: 10.2967/jnumed.121.262485.
    PubMed     Abstract available

  15. SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
    PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
    PubMed     Abstract available

    July 2021
  16. ZHOU X, Jiang J, Yang X, Liu T, et al
    First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
    PubMed     Abstract available

  17. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available

  18. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available

    May 2021
  19. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available

    January 2021
  20. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.

    June 2020
  21. FERDINANDUS J, Barbato F, Chodyla M, Fendler WP, et al
    Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
    J Nucl Med. 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.